FDA-approved peptide medicines: the clearest safety picture
The safest starting point is always an FDA-approved medicine prescribed by a licensed physician. The FDA approval process requires evidence from multiple clinical trials involving thousands of patients before a drug is authorized for market. Post-market surveillance continues after approval.
The approved GLP-1 peptide drugs have some of the most robust safety datasets of any medicines in current widespread use:
- Semaglutide (Ozempic, Wegovy) - studied in the STEP and SUSTAIN trial programs involving tens of thousands of participants. Common side effects include nausea, vomiting, and diarrhea, particularly during dose escalation. Rare but serious risks include pancreatitis, gallbladder disease, and a theoretical thyroid cancer risk based on rodent studies (not observed in humans at current rates, but the warning remains on labeling).
- Tirzepatide (Mounjaro, Zepbound) - studied in the SURMOUNT and SURPASS trial programs. Similar side effect profile to semaglutide, with comparable GI tolerability findings.
- Liraglutide (Saxenda, Victoza) - the earlier-generation GLP-1 with the longest real-world safety record in this class.
- Tesamorelin (Egrifta) - the FDA-approved growth hormone-releasing hormone analogue. Known side effect profile includes injection site reactions, fluid retention, and potential effects on glucose metabolism.
"Safe" for these medicines does not mean side-effect-free - it means the risk-benefit profile has been evaluated and the FDA has determined benefits outweigh risks in the approved patient populations.
Compounded peptides: legitimate but less studied
Compounded peptides occupy a different safety position. When a licensed US compounding pharmacy produces semaglutide or another peptide under proper 503A or 503B standards, the active pharmaceutical ingredient is the same molecule. But:
- The compounded preparation has not been individually reviewed by the FDA
- Quality depends on the specific pharmacy's standards, equipment, and testing protocols
- The FDA has issued warnings about specific compounded formulations - including certain semaglutide salt forms (semaglutide sodium) and inaccurate dosing claims from some compounders
This does not mean compounded peptides are unsafe. It means the safety assurance shifts from the FDA approval process to the quality of the specific pharmacy and the diligence of the prescribing physician.
The FDA's 2024 bulk substance rule changes restricted compounding of many peptides beyond semaglutide and tirzepatide. BPC-157 was placed on the Category II bulk substance list (compounding not permitted under current rules), and several other peptides moved to Category III (under further review). Clinics advertising compounded BPC-157 or restricted peptides today should be able to explain specifically how they comply with current FDA rules. See our guide to what peptides are legal in the US in 2026 for the full breakdown.
Grey-market and research-chemical peptides: a different category entirely
Peptides sold online as "research use only," "not for human use," or through grey-market channels exist entirely outside the clinical safety framework. These products:
- Have not been manufactured to pharmaceutical standards
- Have not been tested for endotoxin levels, sterility, or accurate dosing
- May contain contaminants, incorrect concentrations, or substituted compounds
- Are often sourced from overseas manufacturers with no US regulatory oversight
The FDA has issued multiple warning letters and enforcement actions against suppliers and clinics that direct patients toward research-use peptides. Adverse event reports from self-administered research chemicals are not collected systematically, which means harm from this category is likely underreported.
This is not a theoretical concern. Injection of non-sterile products carries real infection risk. Inaccurate dosing of compounds that affect hormones, immune function, or blood pressure carries real physiological risk.
What physician supervision adds to safety
Physician supervision does not just add regulatory legitimacy - it produces measurably better safety outcomes. A supervising physician:
- Reviews your health history and current medications for contraindications before prescribing
- Orders baseline labs and interprets them in the context of your specific situation
- Starts you at an appropriate dose and titrates based on your response
- Monitors you for side effects through scheduled follow-up appointments
- Adjusts or stops the program if something changes
This is the mechanism by which dose-dependent side effects are caught early, contraindications are identified before harm occurs, and drug interactions are anticipated rather than discovered after the fact.
Questions to ask before starting any peptide program
Before committing to any clinic or program, these questions help establish its safety posture:
- What is the FDA status of the specific peptide being prescribed?
- If it is compounded, which pharmacy produces it and what accreditation does that pharmacy hold?
- What labs are required before prescribing?
- What are the known side effects and contraindications for this specific compound?
- What monitoring is included in the program?
- What should I do if I experience a side effect between appointments?
- Has this clinic received any FDA warning letters or state medical board actions?
A physician-supervised program that answers these questions directly is operating in the legitimate space. See how to find a physician-supervised peptide clinic in the US for a full evaluation framework, and the cost of peptide therapy in the US to understand what proper programs typically cost.
Browse the US directory to compare clinics with physician supervision, telehealth access, and clear service descriptions.
---
*This article is for educational purposes only. Consult a licensed physician before starting any peptide therapy program.*